TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Zota Health Care Limited
ZOTA

Zota Health Care Limited Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 48/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,336.6

Change

-9.1 (-0.68%)

Open

₹1,333.5

Prev. Close

₹1,345.7

Day High

₹1,354.2

Day Low

₹1,326.5

Volume Analysis

Traded

30,110

Delivered

11,329

Delivery %

37.63%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (-15.0%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (48/100)
  • •Low operating margin (0.5%)

Opportunities (2)

  • •Strong 3-year revenue growth (57.0%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,379.4 ₹1,366.8 ₹1,351.7 ₹1,339.1 ₹1,324.0 ₹1,311.4 ₹1,296.3
Fibonacci ₹1,366.8 ₹1,356.22 ₹1,349.68 ₹1,339.1 ₹1,328.52 ₹1,321.98 ₹1,311.4
Camarilla ₹1,344.22 ₹1,341.68 ₹1,339.14 ₹1,339.1 ₹1,334.06 ₹1,331.52 ₹1,328.98

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-12.08%

1 Week

+3.79%

1 Month

+23.45%

3 Months

-5.66%

6 Months

+19.75%

1 Year

-6.52%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-13.36%

Net margin -17.08% × asset turnover 0.48x × equity multiplier 1.63x

Company Overview

Sector

Healthcare

Market Cap

₹4,696 Cr

ROE

-15.0%

Book Value

₹200.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 22 Sep 2026. Not investment advice.

TopFund Analysis

Zota Health Care Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 48/100. The strongest factor is Growth (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-15.0%); promoter holding is falling. Strong 3-year revenue growth (57.0%).

TopFund Score — Fundamentals Quality

48/100 — Weak

Data confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

95

Growth

100

Valuation

15

Cash Flow

0

Corporate Governance

43

Momentum

47

Institutional Ownership

61

Business Quality

20

Risk & Volatility

49

Liquidity

26

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 6.77 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -19.9% over last 3 years.
  • −Promoter holding has decreased over last 3 years: -18.7%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Updates 21 Sep

Zota responds to IiAS against-vote recommendations on 4 AGM resolutions, including MD reappointment and related-party transactions.

Cessation 18 Sep

Mrs. Varshabahen Gaurang Mehta ceased as Independent Director on September 9, 2026.

Copy of Newspaper Publication 06 Sep

Newspaper ads published on September 6, 2026 for 26th AGM, record date and final dividend.

Copy of Newspaper Publication 04 Sep

Newspaper advertisements published for Zota Health Care’s 26th AGM on September 28, 2026.

Shareholders meeting 03 Sep

Board approved 26th AGM on September 28, 2026, 10% final dividend, Mahaveer Dhariwal appointment, and MD reappointment.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 39 45 47 50 56 67 72 97 104 129 143 163 174
Expenses + 37 41 44 51 58 68 78 95 100 123 143 154 185
Operating Profit 1 4 3 -1 -1 -1 -6 2 4 6 0 9 -12
OPM % 3.3% 10.0% 7.0% -3.0% -2.2% -1.3% -8.0% 2.5% 3.8% 4.9% -0.3% 5.0% -7.0%
Other Income + 0 0 0 0 0 1 1 1 1 2 2 -3 2
Interest 1 1 1 2 3 3 2 3 3 4 5 5 6
Depreciation 3 5 5 7 8 10 11 14 15 19 22 27 28
Profit before tax -3 -1 -3 -10 -12 -13 -18 -14 -13 -14 -26 -26 -44
Tax % 1.0% 49.0% 7.0% -27.0% 5.0% -4.0% 2.0% -10.0% 5.0% 13.0% 14.0% -45.0% 1.0%
Net Profit + -3 -2 -3 -7 -13 -12 -19 -13 -14 -16 -30 -14 -44
EPS in Rs -1 -1 -1 -3 -5 -4 -7 -5 -5 -5 -9 -4 -13
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2011 Mar 2012 Mar 2014 Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 25 38 50 56 85 95 106 131 139 180 292 538 609
Expenses + 21 33 43 47 77 90 105 116 132 173 298 520 606
Operating Profit 4 5 6 8 8 5 1 15 7 8 -6 19 3
OPM % 14.0% 13.0% 13.0% 15.0% 9.0% 4.8% 0.6% 11.0% 5.0% 4.2% -2.0% 3.4% 0.5%
Other Income + 0 0 0 0 2 2 2 2 2 1 2 1 3
Interest 0 1 1 1 0 0 0 0 3 5 11 17 20
Depreciation 0 1 1 2 1 2 3 4 12 20 43 82 96
Profit before tax 3 3 5 6 8 4 0 12 -5 -16 -58 -80 -110
Tax % 34.0% 33.0% 33.0% 33.0% 29.0% 29.0% -41.0% 28.0% 23.0% -11.0% -2.0% -7.0% —
Net Profit + 2 2 3 4 6 3 0 9 -6 -14 -57 -74 -104
EPS in Rs 2 1 2 2 2 1 0 4 -2 -6 -20 -21 -31
Dividend Payout % 0.0% 50.0% 38.0% 34.0% 32.0% 90.0% -1,170.0% 42.0% -44.0% -18.0% -5.0% -5.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2011 Mar 2012 Mar 2014 Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 5 3 4 4 51 44 42 64 55 64 195 659
Borrowings + 3 6 5 5 0 0 0 15 45 95 140 270
Other Liabilities + 5 10 14 17 21 20 19 35 33 43 76 167
Total Liabilities 20 29 35 40 90 88 85 139 158 228 439 1,131
Fixed Assets + 8 10 9 8 10 15 14 29 62 103 185 369
CWIP 0 0 0 0 2 0 0 0 3 5 6 15
Investments 0 0 0 0 16 14 10 33 8 5 54 264
Other Assets + 12 19 26 32 63 59 61 77 85 116 193 483
Total Assets 20 29 35 40 90 88 85 139 158 228 439 1,131
Equity Capital 7 10 12 14 18 25 25 25 25 26 29 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2011 Mar 2012 Mar 2014 Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + — — 3 5 -3 6 -1 13 -2 -6 -50 -82
Cash from Investing Activity + — — -1 -1 9 -4 4 -27 15 -13 -92 -330
Cash from Financing Activity + — — -2 -4 -6 -3 -2 14 -14 19 145 503
Net Cash Flow — — 0 0 -1 -1 1 1 -1 0 3 92
CFO/OP — — 78 81 -12 147 -134 115 2 -59 811 -380
Free Cash Flow — — 2 4 -6 -1 -2 10 -13 -23 -96 -208

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 66.16% → 49.38%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 33.83% 33.85% 33.85% 35.55% 36.6% 36.71% 36.33% 34.52% 35.75% 34.06% 36.0% 35.96%
Promoters 66.16% 66.15% 66.15% 64.44% 62.4% 62.02% 59.72% 57.42% 55.81% 50.64% 49.38% 49.38%
FII 0.02% 0.0% 0.0% 0.01% 0.01% 0.24% 0.87% 3.82% 3.49% 8.09% 8.21% 7.92%
DII 0.0% 0.0% 0.0% 0.0% 0.99% 1.03% 3.08% 4.25% 4.95% 7.22% 6.4% 6.75%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Zota Health Care Limited (this stock) 4,696 — 6.78 -15.0%
Sms Pharmaceuticals Ltd. 4,448 43.4 5.66 14.3%
Rpg Life Sciences Ltd 5,045 43.2 8.34 19.3%
Gufic Biosciences Ltd. 4,237 57.7 6.37 10.1%
Aarti Drugs Ltd. 3,991 20.7 2.57 13.4%
Gujarat Themis Biosyn Ltd 5,442 112.0 — —
Unichem Laboratories Ltd 3,870 31.7 1.42 3.17%

Which Mutual Funds Hold Zota Health Care Limited?

Frequently Asked Questions about Zota Health Care Limited

Community Sentiment

What are other investors saying about Zota Health Care Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.